Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes

Authors: Sundar, R., Chia, D.K.A., Zhao, J.J., Lee, A.R.Y.B., Kim, G., Tan, H.L., Pang, A., Shabbir, A., Willaert, W., Ma, H., Huang, K.K., Hagihara, T., Tan, A.L.K., Ong, C.-A.J., Wong, J.S.M., Seo, C.J., Walsh, R., Chan, G., Cheo, S.W., Soh, C.C.C., Callebout, E., Geboes, K., Ng, M.C.H., Lum, J.H.Y., Leow, W.Q., Selvarajan, S., Hoorens, A., Ang, W.H., Pang, H., Tan, P., Yong, W.P., Chia, C.S.L., Ceelen, W., So, J.B.Y.

Source: In ESMO Open September 2024 9(9)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

Authors: Shitara, K., Fleitas, T., Kawakami, H., Curigliano, G., Narita, Y., Wang, F., Wardhani, S.O., Basade, M., Rha, S.Y., Wan Zamaniah, W.I., Sacdalan, D.L., Ng, M., Yeh, K.H., Sunpaweravong, P., Sirachainan, E., Chen, M.-H., Yong, W.P., Peneyra, J.L., Ibtisam, M.N., Lee, K.-W., Krishna, V., Pribadi, R.R., Li, J., Lui, A., Yoshino, T., Baba, E., Nakayama, I., Pentheroudakis, G., Shoji, H., Cervantes, A., Ishioka, C., Smyth, E.

Source: In ESMO Open February 2024 9(2)

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

Authors: André, T., Vernerey, D., Im, S.A., Bodoky, G., Buzzoni, R., Reingold, S., Rivera, F., McKendrick, J., Scheithauer, W., Ravit, G., Fountzilas, G., Yong, W.P., Isaacs, R., Österlund, P., Liang, J.T., Creemers, G.J., Rakez, M., Van Cutsem, E., Cunningham, D., Tabernero, J., de Gramont, A.

Source: In Annals of Oncology February 2020 31(2):246-256

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Authors: Tai, W.M., Yong, W.P., Lim, C., Low, L.S., Tham, C.K., Koh, T.S., Ng, Q.S., Wang, W.W., Wang, L.Z., Hartano, S., Thng, C.H., Huynh, H., Lim, K.T., Toh, H.C., Goh, B.C., Choo, S.P. ^*

Source: In Annals of Oncology December 2016 27(12):2210-2215

653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors

Authors: Ng, M.C.H., Yong, W.P., Meric-Bernstam, F., Lentz, R.W., Srirangam, V., Cometa, J.R., Blanchard, S., Nellore, R., Tan, A., Lee, Y-A., Lim, J., Gan, S., Koh, C., Adanan, Q., Joy, J., Pendharkar, V., Yeong, J.P.S., Diermayr, V.

Source: In Annals of Oncology September 2024 35 Supplement 2:S516-S516

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

Authors: Yong, W.P., Goh, B.C. ^*, Soo, R.A., Toh, H.C., Ethirajulu, K., Wood, J., Novotny-Diermayr, V., Lee, S.C., Yeo, W.L., Chan, D., Lim, D., Seah, E., Lim, R., Zhu, J.

Source: In Annals of Oncology November 2011 22(11):2516-2522

Population Pharmacokinetics of Modafinil and Its Acid and Sulfone Metabolites in Chinese Males

Authors: Seng, K.-Y., Fan, L., Lee, H.S., Yong, W.P., Goh, B.C., Lee, L.S.-U.

Source: THERAPEUTIC DRUG MONITORING. 33(6):719-729

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN303768024&indx=1&recIds=ETOCRN303768024

Recent progress and clinical importance on pharmacogenetics in cancer therapy

Authors: Soh, T.I.P., Yong, W.P., Innocenti, F.

Source: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 49(10):1621-1632

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN301258912&indx=1&recIds=ETOCRN301258912

Germline Genetic Testing to Predict Drug Response and Toxicity in Oncology- Reality or Fiction?

Authors: Soh, T.I.P., Yong, W.P.

Source: ANNALS- ACADEMY OF MEDICINE SINGAPORE. 40(8):350-355

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN298534756&indx=1&recIds=ETOCRN298534756

Impact of Sample Heterogeneity on Methylation Analysis

Authors: Loh, M., Liem, N., Li Lim, P., Vaithilingam, A., Cheng, C.L., Salto-Tellez, M., Yong, W.P., Soong, R.

Source: DIAGNOSTIC MOLECULAR PATHOLOGY. 19(4):243-247

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN282736110&indx=1&recIds=ETOCRN282736110

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9

Authors: Yong, W.P., Kim, T.W., Undevia, S.D., Innocenti, F., Ratain, M.J.

Source: EUROPEAN JOURNAL OF CANCER. 45(11):1904-1908

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN254434976&indx=1&recIds=ETOCRN254434976

146P Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study

Authors: Lee, K-W., Kang, Y-K., Chen, M-H., Hirano, H., Sunakawa, Y., Kim, S.T., Lin, C-C., Yong, W.P., Kawakami, T., Oshima, T., Li, Z., Hopkins, M., Levin, A., Wang, H., Goldstein, L., Zhou, D., Rha, S.Y.

Source: In Annals of Oncology November 2023 34 Supplement 4:S1530-S1530

LBA7 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup

Authors: Yoshino, T., André, T., Kim, T.W., Yong, W.P., Shiu, K-K., Vittrup Jensen, B., Jensen, L.H., Punt, C.J.A., Smith, D., Garcia-Carbonero, R., Alcaide-Garcia, J., Gibbs, P., de la Fouchardiere, C., Rivera, F., Elez Fernandez, M.E., Le, D.T., Zuo, Y., Fogelman, D., Adelberg, D.E., Diaz, L.

Source: In Annals of Oncology November 2023 34 Supplement 4:S1502-S1503

82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

Authors: Choo, J., Nathan Jeraj, S., Chan, G., Sundar, R., Yong, W.P., Lee, M., Ngoi, N.Y.L., Wong, A., Soo, R.A., Chee, C.E., Lim, J., Goh, B-C., Lee, S.C., Tan, D.S.

Source: In Annals of Oncology November 2023 34 Supplement 4:S1498-S1498

1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases

Authors: Sundar, R., Chia, D., Ceelen, W., Chia, C., Kim, G., Shabbir, A., Willaert, W., Ong, J., Wong, J., Seo, C.J., Tan, H.L., Callebout, E., Geboes, K., Ng, M.C.H., Lum, J., Leow, W.Q., Selvarajan, S., Hoorens, A., Yong, W.P., So, J.B.Y.

Source: In Annals of Oncology October 2023 34 Supplement 2:S869-S869

2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma

Authors: Low, Q.J., Looi, W.D., Sukumar, S.J., Ang, Y., Wong, A.S., Soo, R.A., Sundar, R., Lum, J., Chee, C.E., Bonney, G. Kunnath, Tan, H.L., Yong, W.P.

Source: In Annals of Oncology October 2023 34 Supplement 2:S1170-S1170

267TiP CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.

Authors: Yong, W.P.¹ (AUTHOR), Naito, Y.² (AUTHOR), Hirano, H.³ (AUTHOR), Li, J.⁴ (AUTHOR), Kurokawa, Y.⁵ (AUTHOR), Komatsu, Y.⁶ (AUTHOR), Ozaka, M.⁷ (AUTHOR), Iwatsuki, M.⁸ (AUTHOR), Chen, J-S.⁹ (AUTHOR), Yen, C-C.¹⁰ (AUTHOR), Zalcberg, J.R.¹¹ (AUTHOR), Roy, A.C.¹² (AUTHOR), Chen, L-T.¹³ (AUTHOR), Zhou, Y.¹⁴ (AUTHOR), Nishida, T.¹⁵ (AUTHOR), Doi, T.¹⁶ (AUTHOR)

Source: Annals of Oncology. 2024 Supplement 4, Vol. 35, pS1504-S1504. 1p.

Subject Terms: *GASTROINTESTINAL stromal tumors, *IMATINIB

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer

Authors: Soo, R.A., Wang, L.Z., Tham, L.S., Yong, W.P., Boyer, M., Lim, H.L., Lee, H.S., Millward, M., Liang, S., Beale, P., Lee, S.C., Goh, B.C. ^*

Source: In Annals of Oncology July 2006 17(7):1128-1133

1255P da VINci: Safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer

Authors: Choo, J., Rha, S.Y., Jung, M., Tan, H.L., Chan, G., Ho, J.S., Walsh, R.J., Chee, C.E., Raghav, S., Yong, W.P.

Source: In Annals of Oncology September 2022 33 Supplement 7:S1121-S1121

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)

Authors: Lim, J., Raghav, S., Wong, A., Yong, W.P., Soo, R.A., Chee, C.E., Lee, S.C., Goh, B-C., Dent, R.A., Chan, J.J., Wong, K.Y.K., d/o Nathan Jeraj, S., Kwok, L., Schiavon, G., Foxley, A., Tan, D.S.

Source: In Annals of Oncology September 2022 33 Supplement 7:S748-S748